{
    "ticker": "DRMAW",
    "name": "Dermata Therapeutics, Inc.",
    "description": "Dermata Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of dermatological conditions. Founded in 2016 and headquartered in San Diego, California, Dermata is dedicated to improving the lives of patients with skin disorders through its proprietary drug delivery systems and advanced formulations. The company is especially known for its lead product candidate, DMT310, which is being developed for the treatment of acne and other skin conditions. Dermata's technology leverages a unique drug delivery platform that enhances the effectiveness and convenience of topical treatments. The company's mission is to provide effective and safe solutions that address unmet medical needs in dermatology. Dermata aims to revolutionize the way dermatological disorders are treated, combining scientific innovation with patient-centric approaches. Through its ongoing clinical trials and research initiatives, Dermata is committed to bringing new therapies to market that can significantly improve patients' quality of life while minimizing side effects and treatment burdens.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2016",
    "website": "https://www.dermatarx.com",
    "ceo": "Dr. Philip A. E. D. J. G. M. Ma",
    "social_media": {
        "twitter": "https://twitter.com/DermataTx",
        "linkedin": "https://www.linkedin.com/company/dermata-therapeutics"
    },
    "investor_relations": "https://www.dermatarx.com/investors",
    "key_executives": [
        {
            "name": "Dr. Philip A. E. D. J. G. M. Ma",
            "position": "CEO"
        },
        {
            "name": "Dr. John M. G. H. D. R. Y. McCauley",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "DMT310"
            ]
        }
    ],
    "seo": {
        "meta_title": "Dermata Therapeutics, Inc. | Innovative Dermatological Therapies",
        "meta_description": "Explore Dermata Therapeutics, Inc., a biotechnology company dedicated to developing innovative treatments for dermatological conditions. Discover their lead product DMT310 and commitment to patient care.",
        "keywords": [
            "Dermata Therapeutics",
            "DMT310",
            "Dermatology",
            "Biotechnology",
            "Acne Treatment",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does Dermata Therapeutics focus on?",
            "answer": "Dermata Therapeutics focuses on developing innovative therapies for dermatological conditions."
        },
        {
            "question": "What is Dermata's lead product candidate?",
            "answer": "Dermata's lead product candidate is DMT310, being developed for the treatment of acne."
        },
        {
            "question": "Where is Dermata Therapeutics headquartered?",
            "answer": "Dermata Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "When was Dermata Therapeutics founded?",
            "answer": "Dermata Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "VRTX",
        "AMGN",
        "PFE"
    ],
    "related_stocks": [
        "JNJ",
        "BMY",
        "MRNA",
        "ABBV"
    ]
}